Dakota Wealth Management Sells 393 Shares of Becton, Dickinson and Company (NYSE:BDX)

Dakota Wealth Management lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,711 shares of the medical instruments supplier’s stock after selling 393 shares during the period. Dakota Wealth Management’s holdings in Becton, Dickinson and Company were worth $5,606,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $33,000. Tompkins Financial Corp boosted its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC boosted its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,844 shares of company stock valued at $2,210,716 over the last ninety days. 0.36% of the stock is currently owned by insiders.

Analysts Set New Price Targets

BDX has been the topic of several research analyst reports. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Down 1.0 %

BDX stock opened at $238.05 on Thursday. The stock’s 50 day simple moving average is $227.31 and its 200 day simple moving average is $232.79. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $248.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The company has a market cap of $69.04 billion, a P/E ratio of 40.08, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.42 earnings per share. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.75%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.